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a b s t r a c t
Antibody B4e8 exhibits modest cross-neutralizing activity, with preference for HIV subtype B. This
preference might be explained by B4e8's extensive interaction with Arg315, which occurs at the center of
most subtype B V3 sequences but is replaced by Gln in subtype C. The extent to which B4e8's ability to
neutralize subtype C strains is hindered by Gln315 and/or other factors, e.g. epitope masking, is unclear.
We conﬁrmed here that an Arg315-to-Gln substitution in a subtype B virus abrogates B4e8 neutralizing
activity. Conversely, B4e8-resistant subtype C viruses were rendered sensitive upon Gln 315-to-Arg
substitution. V2 region swapping between B4e8-sensitive and- resistant subtype C strains revealed a role
for V2 in limiting B4e8 access, but this was less signiﬁcant than the absence of Arg315. Our ﬁndings,
while illustrating the importance of Arg315 for B4e8, suggest that some subtype C strains may be
vulnerable to B4e8 derivatives capable of binding stronger to Gln315-containing sequences.
& 2014 Elsevier Inc. All rights reserved.
Introduction
The extraordinary sequence diversity displayed by the HIV-1
envelope spike (Env) poses problems for the design of a vaccine
component that elicits antibodies with broad neutralizing activity.
The third variable (V3) region is one of the ﬁrst neutralizing
antibody (nAb) targets during infection with HIV subtype B but,
strikingly, not other subtypes (reviewed in (Overbaugh and Morris,
2012)), suggesting relative differences in V3 exposure in the
context of subtype B versus non-subtype B viruses. There has
been much skepticism towards targeting V3 in a vaccine formula-
tion because of the general inability of V3-speciﬁc monoclonal
antibodies (mAbs) to neutralize viral isolates across many different
subtypes (Agarwal et al., 2011; Binley et al., 2004; Cardozo et al.,
2009; Eda et al., 2006; Zolla-Pazner et al., 2004).
The limited neutralization breadth of V3 mAbs is often attrib-
uted to masking of the V3 region by other variable loops,
particularly V1V2 (Agarwal et al., 2011; Hatada et al., 2010;
Krachmarov et al., 2006; Liu et al., 2011; Rusert et al., 2011;
Sagar et al., 2006; Saunders et al., 2005; van Gils et al., 2011).
Because the V3 region is more conserved in non-subtype B viruses
than subtype B viruses, there has been a tendency to assume that
V3 is masked to a greater extent in non-subtype B viruses (Hartley
et al., 2005). Indeed, many well-characterized V3 mAbs preferen-
tially neutralize subtype B viruses or chimeric viruses containing
subtype B-derived V3 sequences (Agarwal et al., 2011; Almond
et al., 2012; Corti et al., 2010; Krachmarov et al., 2006; Pantophlet
et al., 2007; Salomon et al., 2014). However, the V3 region, along
with the V1V2 variable regions, has re-gained interest over the last
few years as a possible target for vaccine design. For example,
antibodies of unprecedented neutralization breadth and potency
that target sequence-conserved elements in V1, V2 and V3 have
been described (Walker et al., 2011; Walker et al., 2009). Further-
more, antibodies to a segment in V2 were identiﬁed as an inverse
correlate of risk for infection in a subset of vaccinees in the RV144
HIV clinical trial (Liao et al., 2013). A greater understanding of
different modes of antibody recognition of sequence-conserved
segments within otherwise variable regions should reveal sites of
HIV-1 envelope vulnerability and thus may provide new options
for improvements to immunogen design and perhaps inform
analyses of vaccine-induced antibody responses.
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We have been using V3 mAb B4e8 to gain a better under-
standing of V3 accessibility on HIV. MAb B4e8 is one of just a few
V3 mAbs that neutralize a modest number of clinically relevant
HIV strains (Hioe et al., 2010; Pantophlet et al., 2007). X-ray
crystallography of a B4e8:V3 peptide complex showed previously
that B4e8 interacts primarily with V3 through side-chain contacts
with just two residues, Ile309 and Arg315, with the majority of
interactions occurring with Arg (Bell et al., 2008). The extensive
Arg315 interaction could explain B4e8 poor neutralizing activity
against non-subtype B virus strains (Pantophlet et al., 2007),
as these typically have a Gln at position 315 rather than Arg.
Modeling of the Arg-to-Gln mutation suggests that many of the
antibody contacts (e.g., several van der Waals contacts with Tyr32
and the salt bridge with Asp92 in the B4e8 light chain) would not
be formed ((Bell et al., 2008) and Fig. 1). However, B4e8 was able
to neutralize select non-subtype B viruses (Pantophlet et al., 2007),
albeit at high antibody concentrations, for example 93MW960
(subtype C; IGPGQTF) and 92UG046 (subtype D; IGLGQAY)
(the location of residues important for B4e8 binding based on
epitope mapping (Pantophlet et al., 2007) are underlined), both of
which have a Gln at position 315. B4e8's inability to neutralize
other non-subtype B strains is thus not fully clear. One possibility
is that the B4e8 epitope on other non-subtype B viruses is not
accessible due to epitope masking (Krachmarov et al., 2005).
Here, we sought to better understand factors that might limit
B4e8 binding to the V3 region of non-subtype B strains. We focused
on subtype C given its importance to the worldwide epidemic and
planned vaccine trials and concentrated particularly on exploring
the signiﬁcance of the conserved Gln at position 315. Our results
show that the absence of Arg at position 315, and to a lesser extent
any epitope masking by the V2 region, is hindering B4e8 neutrali-
zation of non-subtype B strains. The rendering of two subtype C
viruses sensitive to B4e8 neutralization upon substituting Gln315
for Arg suggests that the V3 region on at least some non-subtype B
strains may be vulnerable to B4e8-derivatives if capable of achiev-
ing high afﬁnity binding to Gln315-containing V3 sequences.
Results
Select subtype C strains are sensitive to B4e8 neutralizing activity
B4e8 has been shown to neutralize select subtype C viruses
with Gln instead of Arg at position 315 (Pantophlet et al., 2007).
We therefore wanted to ﬁrst assess the neutralizing activity of
mAb B4e8 against additional subtype C strains and chose a 21-
member panel of mostly well-characterized strains (Table 1).
Although B4e8 exhibited poor neutralizing activity against most
of the strains (IC50450 mg/ml), the antibody did neutralize
subtype C strain Du179. A relatively high B4e8 concentration,
relative to the subtype B virus control SS1196, was required for
neutralization of Du179, in line with previous observations of B4e8
requiring relatively high concentrations to neutralize non-subtype
B strains (Pantophlet et al., 2007). The sensitivity of virus Du179 to
B4e8 neutralization conﬁrmed that the V3 region in at least a few
subtype C strains is presented in a way that allows for B4e8 access
and/or sufﬁcient binding afﬁnity despite the presence of a Gln at
position 315. Whether speciﬁc residues in the V3 of virus Du179
might explain its sensitivity to B4e8 remains to be explored fully.
Virus Du179 does contain a positively charged residue (His) at
position 321 in its V3 that is unusual for subtype C viruses, but no
such residue occurs in other non-subtype B viruses that B4e8 has
been shown to neutralize (Pantophlet et al., 2007) and thus the
presense of His321 unlikely explains B4e8's ability to neutralize
virus Du179. Indeed, the crystal structure complex of B4e8 with a
V3 peptide (Bell et al., 2008) shows that the antibody does not
interact with V3 beyond residue 319.
Switching Arg315 to Gln in a subtype B virus with an otherwise
antibody-accessible V3 region confers V3 antibody resistance
In a previous study, B4e8 poorly neutralized HIV strain JRCSF
with an Arg315-to-Gln mutation (Pantophlet et al., 2007). JRCSF is
considered a tier 2 virus (Moore et al., 1995; van Gils et al., 2010)
and thus it is possible that the previous result might have been
inﬂuenced by the relative insensitivity of JRCSF to V3 antibody
neutralization (Binley et al., 2004; Moore et al., 1995). Further-
more, the effect of the Gln substitution on virus sensitivity to non-
V3 antibodies was not investigated. Here, we used the more V3
antibody-sensitive subtype B virus SS1196 to further investigate
the extent to which the presence of Gln at position 315 affects the
ability of B4e8 to exert neutralizing activity. In addition to B4e8,
Fig. 1. Modeling the loss of B4e8 binding interaction upon substituting Arg315 in
V3 with Gln. (A) View of Arg315 and its interactions with B4e8 based on the crystal
structure complex of B4e8 with a subtype B-derived V3 peptide (PDB no. 2QSC (Bell
et al., 2008)). The B4e8 heavy and light chains are shown in cyan and light green,
respectively, and the peptide is shown in yellow. Contacts (gray lines) were
identiﬁed using the Clashes/Contacts feature in UCSF Chimera (Pettersen et al.,
2004) with parameters set to default (van der Waals overlap Z0.4 Å and
contacts of pairs 2 or fewer bonds apart ignored). Based on these parameters,
B4e8 makes a total of 26 contacts with Arg315; most are mediated by Tyr32 and
Aps92 in the light chain. (B) Putative interactions between B4e8 and a V3 with an
Arg-to-Gln substitution at position 315. The Arg was replaced by Gln (tan) using the
Rotamer feature in UCSF Chimera and the speciﬁc rotamer chosen from the
Dunbrack rotamer library (Dunbrack, 2002) based on its high probability. Using
the aforementioned Clashes/Contacts feature, B4e8 would make 40% fewer
contacts with a Gln at position 315 than with Arg315, with the greatest loss from
van der Waals contacts with Tyr32 and the hydrogren bond and salt bridge
to Asp92.
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wild-type and mutant viruses were assessed for sensitivity to the
anti-V3 mAb HGN194, which has shown to have at least equal
neutralization breadth as mAb B4e8, but does not interact with V3
at position 315 (Corti et al., 2010).
We found, as somewhat expected, that mAb B4e8 was incapable
of neutralizing virus SS1196 in which Arg315 had been substituted
by Gln (Fig. 2A, left), thus conﬁrming that the presence of Gln at
position 315 is alone sufﬁcient to severely reduce B4e8's neutraliz-
ing ability. B4e8 bound solubilized gp120 from mutant virus
SS1196_R315Q with substantially lower afﬁnity than wild-type
gp120 (Fig. S1), thus explaining its inability to neutralize
the mutant virus. Unexpectedly, the neutralizing activity of the
Arg315-independent V3 mAb HGN194 was also substantially
reduced (46-fold; po0.0001) relative to the wild-type virus
(Fig. 2A, right). The reduction in neutralizing activity of mAb
HGN194 was speciﬁc to the quaternary context of SS1196 Env;
contrary to B4e8, the Arg-to-Gln mutation did not reduce HGN194's
afﬁnity for solubilized gp120 (Fig. S1). A similar reduction in
neutralizing activity was observed for HGN194 with a JRCSF_R315Q
mutant (Pantophlet et al., 2007) relative to activity against the JRCSF
wild-type virus, (Fig. S2), suggesting that the reduction observed
with SS1196 was not speciﬁc to the SS1196 context.
We used antibodies to epitopes close to V3 (anti-CD4bs mAb
b12) or that involve the V3 region (anti-V2/V3 mAb PG16 and anti-
V3 glycan mAb PGT126) to further assess changes to the oligo-
meric structure of Env due to the Gln substitution. The R315Q
mutant was 4-fold more resistant than wild-type virus SS1196 to
neutralization by b12, but was neutralized as effectively by PG16
as wild-type virus and neutralized 3 better than wild-type
virus by PGT126 (Fig. 2B). These data suggest that altering Arg315
to Gln in SS1196 resulted in some perturbation to the quaternary
organization of Env, including some seclusion of the CD4bs, but
likely not gross conformational changes.
Replacing Gln with Arg at position 315 in V3 renders normally
resistant subtype C viruses sensitive to V3 neutralization
Based on the data above, we considered that the V3 region on
at least some subtype C viruses may be accessible to B4e8 but that
investigating this possibility is complicated by the poor afﬁnity of
B4e8 for V3 sequences with Gln at position 315. We therefore
generated mutants of two B4e8-resistant subtype C viruses
(CAP45 and ZM249M; Table 1) with Gln-to-Arg substitutions at
position 315 and tested them for sensitivity to B4e8 neutralization.
CAP45 and ZM249M are tier 2 subtype C viruses that are generally
resistant to neutralization by V3 mAbs, but not extremely sensitive
or resistant in general to antibody neutralization (Agarwal et al.,
2011; Seaman et al., 2010). Based on the recent crystal structure of
a recombinant gp140 trimer (Julien et al., 2013), mutating Gln to
Arg would not be expected to result in major perturbations to the
oligomeric structure of Env, as Gln315 is too distant to interact
with the neighboring protomer (Fig. S3). Gln315 also does not
form stabilizing intra-residue interactions (Julien et al., 2013).
Contrary to B4e8's inability to neutralize the parental viruses at
concentrations up to 50 mg/ml, we observed that the antibody
effectively neutralized mutants CAP45_Q315R and ZM249M_Q315R
even at low concentrations (Fig. 3, left). Oddly, B4e8 neutralization
curves against the mutant viruses leveled off at around 50% even up
to the highest antibody concentration used (50 mg/ml). MAb neu-
tralization curves that plateau below complete neutralization have
been reported previously, for example with PG16 (Walker et al.,
2009). Quaternary structure heterogeneity of Env on the virion
surface, observable by cryoEM tomography, has been suggested as
one possible explanation for this phenomenon (Frank et al., 2012). A
recent study provides further evidence that certain virus strains can
produce heterogeneous populations of virions despite being geneti-
cally clonal (Roederer et al., 2014).
Given the increased sensitivity of the twomutant subtype C viruses
to mAb B4e8, we also investigated the sensitivity of the two mutant
subtype C viruses to mAb HGN194. We found that the Gln-to-Arg
substitution also rendered the mutant viruses more sensitive to the
neutralizing activity of mAb HGN194 relative to the parental viruses,
albeit that the increase in sensitivity was less substantial than with
B4e8 and not statistically signiﬁcant (Fig. 3, right). As with mAb B4e8,
neutralization levels for mAb HGN194 plateaued at around 50%.
To assess whether the increased sensitivity of the subtype C
mutant viruses was limited to V3 or due to a more general increase
in virus sensitivity as a result of the Gln-to-Arg change, we
Table 1
HIV-1 strains used in this study and their sensitivity to B4e8 neutralizing activity.
Virus Subtype Accession no. V2 length Tiera V3 sequence IC50 (lg/ml)
SS1196 B AY835442 39 1B CTRPNNNTRKSIHIGPGRAFYATGGVIGDIRQAHC 4.4
HIV-00836-2 C EF117265 39 1B CTRPNNNTRKSIRIGPGQTFYATGEIIGNIRQAHC 450
HIV-001428-2 C EF117266 46 2 CTRPNNNTRKSIRIGPGQTFYATGDIIGNIREAHC 450
HIV-0013095-2 C EF117267 49 2 CTRPNENRRKSIRIGPGQAFYATGDIIGDIRQARC 450
HIV-16055-2 C EF117268 43 2 CTRPNNNTRKSIRIGPGQTFYATGDIIGNIRQAYC 450
HIV-1 16845-2 C EF117269 47 2 CTRPGNNTRKSIRIGPGQTFYATGDIIGDIRQAHC 450
HIV-1 16936-2 C EF117270 43 2 CTRPNNNTRKSVRIGPGQTFYATGEIIGDIRQAHC 450
HIV-25710-2 C EF117271 44 1B CARPSNNTRTSIRIGPGQTFYATGAITGDIRQAHC 450
HIV-1 25711-2 C EF117272 40 1B CIRPNNNTRKSIRIGPGQTFYATGDIVGDIRQAYC 450
HIV-25925-2 C EF117273 44 1B CTRPNNNTRKSIRIGPGQTFYATGAIIGNIREAHC 450
HIV-26191-2 C EF117274 41 2 CTRPGNNTRKSIRIGPGQTFYATGEIIGNIRQAHC 450
Du156 C DQ411852 41 2 CTRPNNNTRKSVRIGPGQTFYATGDIIGDIRQAHC 450
Du172 C DQ411853 45 2 CTRPSNNTRKSVRIGPGQTFFATGDIIGDIRQAHC 450
Du179 C AY043174 37 NA CTRPGNNTRKSIRIGPGQAFYTNHIIGDIRQAYC 22.8
Du422 C DQ411854 43 2 CTRPNNNTRKSVRIGPGQTFYATGEIIGDIREAHC 450
ZM197M C DQ388515 48 1B CVRPNNNTRKSVRIGPGQTFFATGEIIGDIRQAHC 450
ZM249M C DQ388514 41 2 CTRPNNNTRKSIRIGPGQTFYATGEIIGKIREAHC 450
ZM53M C AY423984 41 2 CTRPGNNTRKSIRIGPGQAFFATTNIIGDIRQAYC 450
ZM109F C AY424138 44 1B CIRPGNNTRKSIRLGPGQTFYATGDVIGDIRKAYC 450
ZM214M C DQ388516 42 2 CMRPGNNTRRSVRIGPGQTFYATGEIIGDIRQAHC 450
CAP45 C DQ435682 44 2 CRRPNNNTRKSIRIGPGQAFYATNDIIGDIRQAHC 450
CAP210 C DQ435683 44 2 CIRPGNNTRRSIRIGPGQAFYAMGDIIGNIREAHC 450
NA¼not available.
a Tier designation based on Seaman et al. (2010).
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compared the sensitivity of the wild-type and mutant viruses to
our sentinel mAbs b12, PG16 and PGT126. In striking contrast to
the increased sensitivity of the mutant viruses to the two V3
mAbs, the mutant viruses were generally more resistant to the
activity of the three sentinel antibodies (Fig. S4); for b12 against
virus ZM249M_Q315R, this difference however did not reach
statistical signiﬁcance. The only exception was with mAb PGT126
against virus CAP45_Q315R, which was more sensitive than that
of the wild-type virus. However, this difference was also not
statistically signiﬁcant. Thus, the increased sensitivity of these
subtype C viruses to B4e8 upon switching Gln to Arg seems due to
increased binding afﬁnity of the antibody, not a general increase in
virus sensitivity to neutralizing antibodies.
The V2 region in subtype C selectively hinders antibody access to V3
The V1V2 domain is known to play an important role in
limiting antibody access to the V3 region in subtype B tier 2
Fig. 2. Arg315-to-Gln substitution in the V3 antibody-sensitive subtype B virus SS1196 imparts resistance to neutralization by V3 mAbs. (A) Replacing Arg315 with a Gln in
virus SS1196 not only renders it completely resistant to antibodies B4e8 but also substantially reduces its sensitivity to the neutralizing activity of the Arg315-independent
mAb HGN194. (B) Changing Arg315 to Gln in virus SS1196 results in somewhat reduced accessibility of the CD4bs, as assessed by the CD4bs-speciﬁc neutralizing mAb b12.
The effect appears to be local, as no global changes were evident as shown by the similarity in neutralization sensitivity between wild-type and mutant viruses when
assessed by PG16 and PGT126 that bind epitopes involving V3 (Walker et al., 2011; Walker et al., 2009). Data are from two or more independent experiments in which each
sample condition was conducted in duplicate. Error bars represent the standard error of the mean and horizontal dotted lines represent IC50 values. Denoted P values are
based on statistical comparison (Fisher's exact test) of the ﬁtted IC50 values from each two neutralization curves (wild-type vs mutant virus). ns, not signiﬁcant (P40.05).
Fig. 3. Mutating Gln315 to Arg in V3 renders neutralization-resistant subtype C viruses sensitive to neutralization by V3 mAbs. CAP45 and ZM249M wild-type (■ and ▲,
respectively) and Q315R mutant viruses (& and n respectively) were assayed for neutralization sensitivity to V3 mAbs B4e8 (left) and HGN194 (right). Data are from two
independent experiments with sample conditions conducted in duplicate. Error bars denote the standard error of the mean. Dashed horizontal lines represent 50%
neutralization. B4e8 did not neutralize either wild-type virus, but neutralized both CAP45_Q315R and ZM249M_Q315R mutant viruses potently. Neutralization curves for
both mutant viruses however plateaued around 50% ns, not signiﬁcant (P40.05).
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and 3 viruses (Krachmarov et al., 2005; Krachmarov et al., 2006;
Liu et al., 2011; Pinter et al., 2004; Rusert et al., 2011). To
investigate the extent to which this occurs in subtype C viruses,
we exchanged the V2 region of the V3 antibody-resistant virus
ZM249M and the V2 region of the B4e8-sensitive virus Du179,
which we found was sensitive also to mAb HGN194. Placing the
Du179 V2 region in the ZM249M background rendered the
chimeric virus at least as sensitive as virus Du179 to neutralization
by HGN194 (Fig. 4, right). These results suggested that the V2
region on ZM249M, like the V2 region of tier 2 subtype B viruses
such as JR-FL and YU2 (Krachmarov et al., 2006; Pinter et al.,
2004), serves to restrict antibody access to the V3 region. However,
and unexpectedly, the ZM249M_Du172V2 mutant virus remained
as resistant to mAb B4e8 as the parental ZM249M virus (Fig. 4,
left). Conversely however, virus Du179 transplanted with the
ZM249M V2 region was rendered resistant to the neutralizing
activities of both B4e8 and HGN194 (Fig. 4), further substantiating
a role for the V2 region of virus ZM249M, and presumably also the
V2 region of other tier 2 subtype C strains, in hindering antibody
access, particularly of mAb HGN194, to the subtype C V3 region.
Using mAbs b12, PG16 and PGT126, we again assessed the
extent to which V2 region swapping might have resulted in gross
alterations to Env. Placing the ZM249M V2 region into Du179
rendered the virus substantially resistant to neutralization by mAb
b12, similar to B4e8 and HGN194, but highly sensitive to mAbs
PG16 and PGT126 (Fig. S5). For virus ZM249M_Du179V2, nearly
the opposite was observed; the V2 region substitution rendered
the mutant virus substantially more sensitive to b12 neutraliza-
tion, somewhat more sensitive to PG16 and signiﬁcantly more
resistant to mAb PG16 (Fig. S5). These results show that V3
antibody sensitivity or resistance of the respective V2 mutant
virus was not due to an Env spike in which multiple epitopes are
simultaneously exposed or occluded; rather, the changes cause
perturbations that have varying effects on antibody sensitivity.
Improved B4e8 afﬁnity for subtype C V3 is sufﬁcient to overcome
epitope masking by the V2 region
The unexpected insensitivity of mutant virus ZM249M_Du172V2
to neutralization by mAb B4e8 led us to consider whether this might
be overcome by substituting the Gln at position 315 for Arg,
thus improving B4e8's afﬁnity for the target sequence. This change
indeed rendered the virus sensitive to B4e8 neutralizing
activity (Fig. 5), suggesting that mAb B4e8 neutralization may be
dependent to a greater extent on the presence of Arg at position 315
than access restrictions imposed by V2. This mutant virus
(ZM249M_Q315R_Du172V2) was somewhat more sensitive to B4e8
neutralization than ZM249M with only the Gln315-to-Arg change
(ZM249M_Q315R), suggesting that any effect exerted by the V2
region of ZM249M in limiting B4e8 access to the V3 region is
modest. Introduction of the Gln315-to-Arg change in virus Du179
rendered the virus non-infectious, thus precluding our ability to
investigate whether, and if so the extent to which, the resistance of
mutant virus Du179 with the ZM249M V2 region to mAb B4e8 can
be rescued by presenting a V3 for which the antibody has higher
afﬁnity.
Discussion
Comparably little attention has been given to V3 exposure in
subtype C viruses. One possible reason is the perception that V3
antibodies play a limited role in neutralization of these viruses
during infection. Indeed, individuals infected with subtype C HIV
tend to mostly develop nAbs directed towards regions outside of
V3 (Gray et al., 2007; Gray et al., 2009; Lynch et al., 2011; Moore
et al., 2009); in those instances where V3 antibodies are detected
they tend not to exhibit HIV neutralizing activity (Davis et al.,
2009; Moore et al., 2008). The purpose of this study was to gain
better insight into the factors that limit neutralization of subtype C
viruses by the modestly cross-neutralizing mAb B4e8 and, perhaps
more generally, increase our understanding of how speciﬁc fea-
tures of the HIV envelope spike protect the virus from antibody
recognition. Mutating Gln315 to Arg in the V3 region of two tier
2 subtype C viruses rendered them sensitive to neutralization by
B4e8 (Figs. 3 and 5), thus illustrating the importance of Arg by
effective neutralization of subtype C viruses by B4e8 but suggest-
ing also that the V3 region on at least some subtype C viruses may
Fig. 4. The V2 region of subtype C viruses modulates access to V3. Du179 and ZM249M wild-type (● and ♦, respectively) and respective mutants containing the V2 region of
the other virus (J and , respectively) were tested for sensitivity to V3 mAbs B4e8 (left) and HGN194 (right). Data are from two independent experiments, with conditions
performed in duplicate. Dashed horizontal lines represent 50% neutralization. The results show that virus susceptibility to neutralization by mAb HGN194 can be transferred
by swapping of the V2 regions between sensitive (Du179) and resistant virus (ZM249M). In contrast, the resistant virus (ZM249M) to mAb B4e8 is not rendered sensitive by
incorporating the V2 region of the sensitive virus (Du179) but resistance is conferred to the sensitive virus by replacing its V2 region with that of the resistant one.
Fig. 5. Efﬁcacious B4e8 neutralization of non-subtype B viruses is more severely
hampered by the absence of Arg at position 315 than by access limitations imposed
by the V2 region. An Arg, introduced into the B4e8-resistant mutant virus
ZM249M_Du179V2, rendered the virus substantially sensitive to neutralization
(calculated IC50¼0.08 mg/ml). Data are from two independent experiments. A
small statistical difference was observed between B4e8's neutralizing activity
against virus ZM249M_Du179V2 and virus ZM249M_Q315R_Du179V2.
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be accessible to B4e8-like antibodies with strong afﬁnity for
Gln315-containing V3 sequences.
The V3 region is often considered occluded or masked, in
particular on HIV strains that on average have moderate (tier 2)
or low (tier 3) sensitivity to antibody-mediated neutralization, yet
how this occurs or is modulated has not been fully dissected.
The V1V2 domain has been shown to be a major determinant of
V3-targeted resistance in subtype B viruses (Krachmarov et al.,
2006; Pinter et al., 2004) and the recent crystal structure of a
soluble HIV-1 Env trimer construct suggests that access to the V3
tip in native Env expressed on the surface of tier 2 and 3 viruses
may be occluded by a glycan attached to Asn197 in the V2 region
of the neighboring gp120 protomer (Julien et al., 2013). The extent
to which epitope masking hinders B4e8 neutralization of subtype
C viruses remains to be investigated, as is the possible relation
between epitope masking and inability of B4e8 to fully neutralize
subtype C viruses with a Gln315-to-Arg mutation as shown here
(Fig. 5).
To the best of our knowledge, our study is the ﬁrst to
speciﬁcally investigate the inﬂuence of Gln on the neutralizing
activity of antibody B4e8 in tier 2 subtype C viruses and the
possible role of V2 in regulating V3 access on subtype C viruses.
Past studies have used other V3 mAbs along with the highly
neutralization sensitive subtype B virus SF162 harboring non-
subtype B consensus V3 motifs to investigate the inﬂuence of
Gln on antibody binding/neutralization (Cardozo et al., 2009;
Krachmarov et al., 2006; Salomon et al., 2014). However, the
context-dependent effects of other altered or introduced residues
on antibody recognition as a result of using consensus sequences
are not clear and will require further investigation. Here, we chose
to introduce the R315Q mutation in the subtype B virus SS1196
which, unlike SF162, has features, including V1V2 length (60
residues) and glycosylation sites (n¼5), that more closely resem-
ble those of V3-antibody resistant subtype B viruses (Li et al.,
2005) and similar to the features of the subtype C viruses used in
this study.
It is worth noting that our observations do not signify that
factors or residues other than those mentioned above cannot also
contribute to differences in V3 exposure levels, for example the
possible role of Ile309 in subtype C in also modulating V3
exposure (Lynch et al., 2010). In this regard, the importance of
the aforementioned glycan at Asn197 in limiting V3 access in
subtype C viruses (Julien et al., 2013) remains to be investigated
more fully vis-à-vis the spectrum of neutralizing activity exhibited
by different V3 antibodies against the same HIV strain (Gorny
et al., 2006; Hioe et al., 2010; Pantophlet et al., 2008). We view this
study therefore as an extension of our previous work (Bell et al.,
2008; Pantophlet et al., 2007) in seeking to understand the
neutralizing activity of anti-V3 antibodies, in particular mAb
B4e8, relative to their epitope speciﬁcity. Although we had shown
previously that Arg315 is important for B4e8's binding interaction,
we had not yet explored the extent to which Gln impacts B4e8's
ability to neutralize subtype C strains. This question was of
particular interest given that B4e8 can neutralize select non-
subtype B viruses with a Gln at position 315 (Pantophlet et al.,
2007). Here we identiﬁed yet another subtype C virus (Du179) that
is sensitive to B4e8 neutralization.
To what extent then is the V3 tip on non-subtype B viruses
accessible to bona ﬁde V3-speciﬁc antibodies? Failure to recover
broadly neutralizing V3-speciﬁc mAbs from individuals infected
with non-subtype B viruses may not be an adequate measure of
the degree of accessibility of the V3 tip on these viruses. For
example, the V1V2 region was long considered as highly variable
and an unlikely target for broadly neutralizing antibodies, yet the
discovery of the PG9/16 antibodies and related ones (e.g. CH01-04
and PGT141-145) has made clear that some segments of V1V2 are
highly conserved and accessible (McLellan et al., 2011). Of rele-
vance to this study is that not all antibodies to the PG9/16 epitopes
exhibit broad anti-viral activity because of critical differences in
ﬁne speciﬁcity (Doria-Rose et al., 2012; Wu et al., 2011) or
structural polymorphism that affects the manner of antibody
interaction with the epitope.
One potential alternative avenue to assess V3 exposure on non-
subtype B viruses is the in vitro evolution of existing V3 mAbs, as
has been done for other anti-HIV antibodies (Barbas et al., 1994;
Diskin et al., 2011; Nelson et al., 2007), and subsequent investiga-
tion of the neutralizing activity of the recovered variants relative
to their afﬁnity for non-subtype B V3 sequences. We do recognize
that despite the increased sensitivity to neutralization caused by
the Q315R mutation, B4e8 neutralization of the mutated clade C
viruses plateaued between 50% and 70% neutralization; whether
B4e8 derivatives capable of binding wild-type subtype C V3
sequences with higher afﬁnity would exhibit similar behavior
needs to be determined empirically. The mutant viruses generated
in this study should be helpful in this regard. Information gained
from such analyses should provide further insight into epitope
access restrictions on HIV and, more broadly, aid in understanding
links between antibody speciﬁcity and functional activity.
Materials and methods
Antibodies
The anti-V3 mAbs B4e8 (also known as F425-B4e8) and
HGN194 were utilized in this study. The detailed characterization
of these mAbs has been reported previously (Corti et al., 2010;
Pantophlet et al., 2007). MAb b12 to the CD4bs (Burton et al., 1994;
Roben et al., 1994), PG16 to a complex glycopeptide epitope
involving the V2 and V3 regions (Pancera et al., 2013; Walker et
al., 2009) and PGT126 to a carbohydrate epitope involving Asn332
in V3 (Walker et al., 2011) were used as sentinels in neutralization
experiments to assess possible changes in Env oligomeric structure
from mutations. MAb EH21, which binds a fairly conserved
discontinuous epitope in the C1 region of gp120 (Haynes et al.,
2005), was used as a control in ELISA experiments. All aforemen-
tioned antibodies were used in this study as whole IgGs.
Expression and puriﬁcation of mAb B4e8
Synthetic genes encoding B4e8 heavy and light chains were
purchased (DNA 2.0, Menlo Park, CA) and cloned into the bicis-
tronic vector pBudCE4.1 (Invitrogen), modiﬁed so as to contain
the CH2 and CH3 constant domains of IgG1 for expression of full-
length IgG molecules. A stable CHO-K1 cell line expressing
recombinant B4e8 was generated by transfection with FuGene 6
(Roche) and limiting dilution selection in the presence of zeocin
(200 mg/ml; Invivogen). Clones producing the highest levels of
protein from two limiting dilution rounds were sub-cultured to
select the best-growing clone. To maximize production, the stably
transfected clone was cultured in multi-level Cell Factories (Nunc).
Supernatants were normally harvested at 10-day intervals, ﬁltered
to remove cell debris and then puriﬁed on a protein A column
(Pierce) following standard protocols. The eluate was buffer-
exchanged into Tris/HCl (0.1 M, pH 8) and protein purity then
assessed by SDS-PAGE.
Pseudoviruses
A panel of 21 wild-type subtype C strains were used in this
study (Table 1); roughly half are derived from recently infected
individuals in South Africa and Zambia (Li et al., 2006; van
S. Manhas et al. / Virology 462-463 (2014) 98–106 103
Harmelen et al., 2001) while the rest are from newly acquired
infections in India (Kulkarni et al., 2009). With the exception of
strain Du179, all subtype C strains have previously been character-
ized extensively and been designated as moderately sensitive (tier
2) to antibody-mediated neutralization (Seaman et al., 2010).
In addition to the subtype C strains, a wild-type tier 1B subtype
B virus (SS1196) was included that is sensitive to neutralization by
anti-V3 antibodies (Seaman et al., 2010).
Env-pseudotyped viruses were generated by transient co-
transfection of 293T cells with Env expressing plasmid and the
luciferase reporter plasmid pNL4-3.Luc.RE (at a 1:2 ratio as
done previously (Pantophlet et al., 2003)) using polyethylenimine
(25 kDa; Polysciences) or Fugene HD (Promega) as the transfection
reagent. Pseudovirus containing supernatant was harvested at 3 d
post-transfection and used immediately or aliquoted and stored at
80 1C until needed. Point mutations in Env-expressing plasmids
were generated using relevant primers by Quikchange (Strata-
gene). V2-region swaps were generated by ‘Zheng’ mutagenesis
(Zheng et al., 2004) following the recommended primer design.
Amino acid substitutions were veriﬁed by Sanger sequencing. Tier
2 subtype B virus JRCSF and mutant JRCSF-R315Q were from a
previous study (Pantophlet et al., 2007).
Neutralization assays
Analyses of virus neutralization in vitro by antibodies were set
up as previously described (Pantophlet et al., 2003; Zwick et al.,
2001) in duplicates. Serially diluted antibody was incubated for 1 h
at 37 1C with virus before adding to target cells. Luciferase activity
was assayed immediately on a Viktor X5 multi-label plate reader
(PerkinElmer). Percentage neutralization was calculated relative to
cell-only and virus-only controls. Virus-only controls ranged
between 104 and 105 relative luciferase units (RLU), in general
accordance with previously recommended virus input amounts
(Monteﬁori, 2004). No noticeable cytopathic effects were observed.
ELISAs
Pseudovirions contained in supernatants from transiently trans-
fected cells were lysed by the addition of Empigen (to 1% ﬁnal
concentration) and the resulting lysates used in gp120 capture
ELISAs with V3 mAbs as described previously (Pantophlet et al.,
2003).
Statistical analyses
Binding and neutralization curves were ﬁtted using GraphPad
Prism 6 software without further manipulation. Fitted neutraliza-
tion curve midpoints (IC50) were analyzed using the Fisher's exact
test built into the GraphPad software; we applied this feature to
determine the signiﬁcance of neutralization sensitivity differences
between wild-type and mutant viruses (or two mutant viruses).
P valueso0.05 were considered statistically signiﬁcant.
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